NASDAQ : BCRX

BioCryst Pharmaceuticals, Inc.

$9.34 USD

-$0.04 (-0.43%)

Volume
1.85M
Average Volume
4.95M
Market Capitalization
$2.37B
P/E Ratio
-5.40
Dividend Yield
0.00%
Price Target
$17.00
Year High
$11.22
Year Low
$6.00
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.91
Company Overview

NASDAQ

Charles K. Gayer

Biotechnology

Healthcare

BCRX

435

US

USD

https://www.biocryst.com

919 859 1302

09058V103

0000882796

Liquidity Metrics

-1.55

1.91

1.88

0.88

0.00

Sales & Valuation

$874.84M

2.68

-4.09

8.07

1.21

Profitability

$1.21

$263.86M

-51.71%

-51.28%

123.57%

-98.48%

P/E Metrics

-5.40

0.00

0.00

Analyst Price Target & Rating

$17.00

$29.00

$14.00

Sell

2/5

29 Analysts

-45.06%

Financial Health Scores

-5.88

3/9

$178.23M

$465.05M

$1.02B

-$379.02M

Key Metrics (TTM)

$3.06B

3.45

-8.20

1.91

123.57%

-121.96%

-20.24%

12.39%

43 days

Company Executives
Name Title
John Ruesch Chief Technical Operations Officer
Philip George Chief Strategy Officer
Charles K. Gayer CEO, President & Director
Alane Barnes Senior Vice President, Chief Legal Officer & Corporate Secretary
Babar Ghias Chief Financial Officer & Head of Corporate Development
Jinky Ang Rosselli Chief Data Innovation Officer
Stephanie Angelini Chief People Officer & Chief Communications Officer
Nick Wilder Manager of Investor Relations
Yarlagadda S. Babu Chief Discovery Officer
William Sheridan MBBS Chief Development Officer
Poll Results

No votes yet today — be the first to share your view!

About BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA depen ... dent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.

BioCryst to Report Second Quarter 2026 Financial Results on August 5

2026-07-22 07:00:00

RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August 5, 2026.

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

2026-07-15 07:00:00

RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced the appointment of David W. Jenkins, MA, PhD, to the newly created position of Chief Scientific Officer, effective immediately, reporting to Dr. Sandeep Menon, Chief Research and Development Officer. In this role, Dr. Jenkins will build and lead an efficient research team focused on leveraging external innovation, capabilities and partnerships to accelerate the delivery of transformative rare disease therapies to patients. He will be based in the Company's Boston office.

Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet

2026-07-14 10:56:18

The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?

2026-07-08 11:16:12

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-07-02 07:00:00

RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 91,750 shares, of BioCryst common stock. The options and RSUs were granted as of July 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs

2026-06-29 08:21:45

BioCryst Pharmaceuticals said on Monday it would wind down its internal drug discovery programs and close ​its Alabama research facility by the end of ‌2026, as it pivots to external partnerships to build its rare-disease pipeline and streamline expenses.

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

2026-06-29 07:00:00

—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth—

BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up

2026-06-15 13:59:19

BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelling pipeline with Orladeyo and navenibart. BCRX targets $1.8bn in revenues and $1bn in cash by 2033, leveraging best-in-class efficacy and less frequent dosing for navenibart to challenge market incumbents. Recent Q1 results showed 11% YoY Orladeyo revenue growth, robust non-GAAP profitability, and reaffirmed 2026 guidance, suggesting valuation remains attractive.

Frequently Asked Questions

What is the current BioCryst Pharmaceuticals, Inc. (BCRX) stock price?

BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX) stock price is $9.34 in the last trading session. During the trading session, BCRX stock reached the peak price of $11.22 while $6 was the lowest point it dropped to. The percentage change in BCRX stock occurred in the recent session was --0.43% while the dollar amount for the price change in BCRX stock was -$0.04.

BCRX's industry and sector of operation?

The NASDAQ listed BCRX is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of BCRX?

John Ruesch | Chief Technical Operations Officer
Philip George | Chief Strategy Officer
Charles K. Gayer | CEO, President & Director
Alane Barnes | Senior Vice President, Chief Legal Officer & Corporate Secretary
Babar Ghias | Chief Financial Officer & Head of Corporate Development

How many employees does BCRX have?

Number of BCRX employees currently stands at 435. BCRX operates from 4505 Emperor Boulevard, Durham, NC 27703, US.

Link for BCRX official website?

Official Website of BCRX is: https://www.biocryst.com

How do I contact BCRX?

BCRX could be contacted at phone #919 859 1302 and can also be accessed through its website. BCRX operates from 4505 Emperor Boulevard, Durham, NC 27703, US.

How many shares of BCRX are traded daily?

The average number of BCRX shares traded daily for last 3 months was 4.95M.

What is the market cap of BCRX currently?

The market value of BCRX currently stands at $2.37B with its latest stock price at $9.34